Jan. 15, 2017 – Cambridge, Massachusetts. Censa Pharmaceuticals Inc. appointed Dan Levy, PhD as Vice President Manufacturing. Dan has served as a consultant for the past year and has been a significant contributor to Censa’s progress to date. His energetic and collaborative leadership provide cost-effective strategies supporting our various manufacturing projects.View Dan’s full bio.
Oct. 15, 2016 – Cambridge, Massachusetts – Censa Pharmaceutical Inc. appointed Neil Smith, PharmD, MBA as Vice President, Research & Development and as Head Operations. In this role, Dr. Smith brings extensive experience in research, clinical project management operations and regulatory processes for, and approvals of, pharmaceutical therapies. As a Senior Director of External Innovation at Chorus, a division of Eli Lilly, Neil was focused on venture capital backed investments into new company creation of project focused companies. Neil also held direct responsibilities for regulatory filings with major competent authorities globally and for the design and oversight of early phase drug development programs including phase 1 first-in-man clinical trials. He was also a Senior Director of Project Management and Head BD with Flexion.
About Censa Pharmaceuticals:
Censa Pharmaceuticals Inc. is developing medicines to improve the lives of patients with debilitating diseases. Censa lead product CNSA-001 targets orphan metabolic and central nervous system diseases
Head Corporate Development
July 18, 2016 – Cambridge, Massachusetts – Censa Pharmaceutical Inc. completed a Series A round of financing from Arkin Bio Ventures and from senior biopharmaceutical executives. The current financing will allow Censa to aggressively accelerate product development towards regulatory approval in target orphan diseases.